RWJ 314313
Latest Information Update: 18 Dec 2003
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Benzonitrile; Small molecules
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 18 Dec 2003 No development reported - Preclinical for Pain in USA (unspecified route)
- 03 May 2000 New profile
- 03 May 2000 Preclinical development for Pain in USA (Unknown route)